- Home
- GYRE vs ITRN Comparison
GYRE vs ITRN Comparison
Compare GYRE & ITRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- ITRN
- Stock Information
- Founded
- GYRE 2002
- ITRN 1994
- Country
- GYRE United States
- ITRN Israel
- Employees
- GYRE N/A
- ITRN N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- ITRN Electronic Components
- Sector
- GYRE Health Care
- ITRN Technology
- Exchange
- GYRE Nasdaq
- ITRN Nasdaq
- Market Cap
- GYRE 897.1M
- ITRN 810.3M
- IPO Year
- GYRE N/A
- ITRN 2005
- Fundamental
- Price
- GYRE $7.28
- ITRN $35.99
- Analyst Decision
- GYRE Strong Buy
- ITRN Buy
- Analyst Count
- GYRE 1
- ITRN 1
- Target Price
- GYRE $18.00
- ITRN $50.00
- AVG Volume (30 Days)
- GYRE 92.0K
- ITRN 89.1K
- Earning Date
- GYRE 11-12-2025
- ITRN 11-20-2025
- Dividend Yield
- GYRE N/A
- ITRN 5.54%
- EPS Growth
- GYRE N/A
- ITRN 9.57
- EPS
- GYRE 0.02
- ITRN 2.79
- Revenue
- GYRE $102,189,000.00
- ITRN $339,610,000.00
- Revenue This Year
- GYRE $16.80
- ITRN $7.03
- Revenue Next Year
- GYRE $50.29
- ITRN $9.69
- P/E Ratio
- GYRE $428.23
- ITRN $13.02
- Revenue Growth
- GYRE N/A
- ITRN 3.30
- 52 Week Low
- GYRE $6.11
- ITRN $26.16
- 52 Week High
- GYRE $19.00
- ITRN $45.43
- Technical
- Relative Strength Index (RSI)
- GYRE 44.66
- ITRN 49.89
- Support Level
- GYRE $7.20
- ITRN $35.07
- Resistance Level
- GYRE $7.72
- ITRN $36.58
- Average True Range (ATR)
- GYRE 0.28
- ITRN 0.69
- MACD
- GYRE -0.01
- ITRN 0.25
- Stochastic Oscillator
- GYRE 28.58
- ITRN 77.11
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About ITRN Ituran Location and Control Ltd.
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.